Oncosec medical inc (ONCS)
CashFlow / TTM
Jan'20Oct'19Jul'19Apr'19Jan'19Oct'18Jul'18Apr'18Jan'18Oct'17Jul'17Apr'17Jan'17Oct'16Jul'16Apr'16Jan'16Oct'15Jul'15Apr'15Jan'15Oct'14
Operating activities
Net loss

-37,779

-32,460

-30,276

-35,213

-38,390

-40,811

-39,136

-32,595

-27,095

-21,746

-21,449

-22,113

-23,804

-25,454

-26,888

0

0

0

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Depreciation and amortization

233

238

243

244

265

299

334

368

381

381

379

386

393

385

355

316

384

518

664

0

0

0

Amortization of right-of-use asset

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-203

0

0

0

-

-

-

-

Amortization of discount on investments

-

-

51

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

3,000

2,546

3,364

5,335

7,575

9,089

8,252

6,542

4,402

3,423

4,016

0

0

0

-

-

-

-

-

-

-

-

Common stock issued for services

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued for services

-

-

-

-

-

-

1,845

1,443

843

109

0

0

0

0

-

-

-

-

-

-

-

-

Modification of equity award

-

-

135

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency exchange loss, net

321

113

281

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,498

2,547

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-

-

-

-

-

-

-

713

316

-201

130

-6

-419

-223

-855

-14

591

657

1,068

0

0

0

Prepaid expenses and other current assets

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term assets

-41

13

9

5

53

53

49

-22

-70

80

88

164

163

2

-24

0

0

0

-

-

-

-

Accounts payable and accrued liabilities

5,098

1,471

-741

933

1,656

755

1,427

-207

-1,128

-270

-208

-179

-164

129

861

1,064

1,987

1,806

1,068

0

0

0

Accrued compensation related

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation related

-

-

-

-

-

-

955

192

44

-101

-128

-348

-488

-191

-258

0

0

0

-

-

-

-

Other long-term liabilities

-

-

-836

-407

-167

176

331

-36

-14

14

253

590

868

1,363

854

0

0

0

-

-

-

-

Net cash used in operating activities

-31,348

-30,357

-29,003

-27,132

-25,235

-24,920

-23,221

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities
Decrease in accrued other and taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-17,036

-17,581

-17,814

-18,968

-19,299

-18,879

-17,651

0

0

0

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

-

21

323

419

999

1,470

1,806

1,909

1,459

1,412

0

0

0

Maturity of investment securities

-

-

17,236

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Sale of investment securities

-

-

5,977

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

23,203

22,199

-4,317

-9,558

-23,289

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-499

-1,079

-1,550

-1,825

-1,928

-1,478

-1,431

0

0

0

Proceeds from issuance of common stock through ESPP

-

-

27

23

40

29

35

35

-6

-6

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock and/or warrants

-

-

27,897

17,519

38,000

31,000

32,283

32,239

9,283

9,283

0

0

0

0

-

-

-

-

-

-

-

-

Payment of financing and offering costs

-

-

1,159

842

2,752

2,807

3,575

3,592

1,412

1,023

15

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of options

-

-

566

660

729

860

321

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

9,999

9,969

9,576

-4

0

36

22

19

6

0

0

0

-

-

-

-

Principal payments on note payable

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tax withholdings paid on equity awards

66

94

101

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Tax withholdings paid related to net share settlement of equity awards

-

-

32

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Tax shares sold to pay for tax withholdings on equity awards

-58

-75

-83

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

11,941

18,847

27,198

17,109

36,198

38,867

38,883

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

9,232

16,114

16,075

0

0

0

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-18

20

-10

-3

0

0

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-5,987

-2,637

-9,689

-17,301

0

0

0

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Net (decrease) in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,420

-1,853

-7,093

-5,817

0

0

0

Supplemental disclosure for cash flow information:
Interest

0

0

-

-

-

-

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

Interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Income taxes

-

-

-

-

-

-

0

0

0

0

1

1

1

1

2

0

0

0

-

-

-

-

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Noncash investing and financing transactions:
Issuance of common stock in connection with a contractual agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Expiration of warrants

-

-

4,060

100

100

765

1,200

1,200

2,370

1,786

1,479

2,010

1,272

1,191

963

0

0

0

-

-

-

-

Amounts accrued for offering costs

-

-

200

0

0

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

Noncash activity related to the issuance of warrants in-transit

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-